Pricing
Login
Home
Charts
Search
Watchlist
Products

Neuland Laboratories Ltd

NEULANDLAB
₹20,642.00-2.18%20 Nov 2026
Reports
Pharma CRAMS

Neuland Laboratories Ltd

NEULANDLAB
₹20,642.00
-2.18%
20 Nov 2026
Ask AI
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
₹26,483Cr
Close
Close Price
₹20,642.00
Industry
Industry
Pharma CRAMS
PE
Price To Earnings
58.52
PS
Price To Sales
11.48
Revenue
Revenue
₹2,307Cr
Rev Gr TTM
Revenue Growth TTM
50.46%
PAT Gr TTM
PAT Growth TTM
88.44%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Revenue
RevenueCr
393385440311398328293514440776642450
Growth YoY
Revenue Growth YoY%
45.9-5.421.1-25.61.3-14.7-33.465.510.5136.4119.2-12.6
Expenses
ExpensesCr
272278316249311277258359363469419352
Operating Profit
Operating ProfitCr
121107123628751341567730722398
OPM
OPM%
30.927.828.120.021.815.611.830.217.539.634.721.7
Other Income
Other IncomeCr
252546078281288
Interest Expense
Interest ExpenseCr
443122557777
Depreciation
DepreciationCr
151616161617202324252729
PBT
PBTCr
104921304912839181295428719869
Tax
TaxCr
23253217261143314755017
PAT
PATCr
816898331022814974121314852
Growth YoY
PAT Growth YoY%
166.4-20.158.2-63.224.8-58.8-85.8194.9-60.1664.7962.4-46.7
NPM
NPM%
20.717.622.310.625.58.54.818.89.227.423.011.5
EPS
EPS₹
63.452.776.325.679.221.710.875.531.6165.8115.140.2
QuarterDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Revenue
RevenueCr
393385440311398328293514440776642450
Growth YoY
Revenue Growth YoY%
45.9-5.421.1-25.61.3-14.7-33.465.510.5136.4119.2-12.6
Expenses
ExpensesCr
272278316249311277258359363469419352
Operating Profit
Operating ProfitCr
121107123628751341567730722398
OPM
OPM%
30.927.828.120.021.815.611.830.217.539.634.721.7
Other Income
Other IncomeCr
252546078281288
Interest Expense
Interest ExpenseCr
443122557777
Depreciation
DepreciationCr
151616161617202324252729
PBT
PBTCr
104921304912839181295428719869
Tax
TaxCr
23253217261143314755017
PAT
PATCr
816898331022814974121314852
Growth YoY
PAT Growth YoY%
166.4-20.158.2-63.224.8-58.8-85.8194.9-60.1664.7962.4-46.7
NPM
NPM%
20.717.622.310.625.58.54.818.89.227.423.011.5
EPS
EPS₹
63.452.776.325.679.221.710.875.531.6165.8115.140.2

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
5105795276677639379511,1911,5591,4772,0232,307
Growth
Revenue Growth%
8.713.5-8.926.414.422.81.525.330.8-5.237.050.5
Expenses
ExpensesCr
4304734776086617908089191,0961,1541,4481,602
Operating Profit
Operating ProfitCr
801065058102147143272463323575705
OPM
OPM%
15.818.49.68.813.415.715.022.829.721.928.430.6
Other Income
Other IncomeCr
215341621013973037
Interest Expense
Interest ExpenseCr
24211916221814131482428
Depreciation
DepreciationCr
1619222631404953606692104
PBT
PBTCr
426714205310582216401346489609
Tax
TaxCr
1520243725185210186125156
PAT
PATCr
27471216168164164300260364453
Growth
PAT Growth%
70.073.1-74.336.3-1.4397.4-20.9156.283.5-13.339.988.4
NPM
NPM%
5.38.12.32.52.18.66.713.719.317.618.019.6
EPS
EPS₹
30.842.010.813.112.662.949.7127.5233.9202.7283.7352.7
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
5105795276677639379511,1911,5591,4772,0232,307
Growth
Revenue Growth%
8.713.5-8.926.414.422.81.525.330.8-5.237.050.5
Expenses
ExpensesCr
4304734776086617908089191,0961,1541,4481,602
Operating Profit
Operating ProfitCr
801065058102147143272463323575705
OPM
OPM%
15.818.49.68.813.415.715.022.829.721.928.430.6
Other Income
Other IncomeCr
215341621013973037
Interest Expense
Interest ExpenseCr
24211916221814131482428
Depreciation
DepreciationCr
1619222631404953606692104
PBT
PBTCr
426714205310582216401346489609
Tax
TaxCr
1520243725185210186125156
PAT
PATCr
27471216168164164300260364453
Growth
PAT Growth%
70.073.1-74.336.3-1.4397.4-20.9156.283.5-13.339.988.4
NPM
NPM%
5.38.12.32.52.18.66.713.719.317.618.019.6
EPS
EPS₹
30.842.010.813.112.662.949.7127.5233.9202.7283.7352.7
Sales CAGR
1 Year37%
3 Years19%
5 Years17%
TTM50%
EBITDA CAGR
1 Year78%
3 Years28%
5 Years31%
TTM115%
PAT CAGR
1 Year40%
3 Years31%
5 Years35%
TTM88%
Avg. ROCE
1 Year24%
3 Years25%
5 Years21%
TTM28%
CFO / EBITDA
1 Year60%
3 Years68%
5 Years69%
TTM-

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
Equity CapitalCr
999131313131313131313
Reserves
ReservesCr
1785375496866977748289811,2701,5121,8622,017
Current Liabilities
Current LiabilitiesCr
268286367327358369363439428466710619
Non Current Liabilities
Non Current LiabilitiesCr
6954146104163170180147122189345381
Total Liabilities
Total LiabilitiesCr
5248861,0711,1301,2311,3251,3831,5801,8332,1802,9303,030
Current Assets
Current AssetsCr
3143754474535155505817619211,1401,4831,390
Non Current Assets
Non Current AssetsCr
2105116246777167758038199111,0401,4471,640
Total Assets
Total AssetsCr
5248861,0711,1301,2311,3251,3831,5801,8332,1802,9303,030
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
Equity CapitalCr
999131313131313131313
Reserves
ReservesCr
1785375496866977748289811,2701,5121,8622,017
Current Liabilities
Current LiabilitiesCr
268286367327358369363439428466710619
Non Current Liabilities
Non Current LiabilitiesCr
6954146104163170180147122189345381
Total Liabilities
Total LiabilitiesCr
5248861,0711,1301,2311,3251,3831,5801,8332,1802,9303,030
Current Assets
Current AssetsCr
3143754474535155505817619211,1401,4831,390
Non Current Assets
Non Current AssetsCr
2105116246777167758038199111,0401,4471,640
Total Assets
Total AssetsCr
5248861,0711,1301,2311,3251,3831,5801,8332,1802,9303,030

Cash Flow

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
453911705718960237261317347
Investing Cash Flow
Investing Cash FlowCr
-20-42-116-77-49-84-96-62-150-298-424
Financing Cash Flow
Financing Cash FlowCr
-24010512-5-11438-136-692521
Net Cash Flow
Net Cash FlowCr
1-4053-93404244-56
Free Cash Flow
Free Cash FlowCr
26-2-1217984-37173119112-50
CFO To PAT
CFO To PAT%
165.582.593.4425.2353.7234.894.6145.187.0122.095.2
CFO To EBITDA
CFO To EBITDA%
55.736.422.3119.856.3129.042.387.356.598.260.3
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
453911705718960237261317347
Investing Cash Flow
Investing Cash FlowCr
-20-42-116-77-49-84-96-62-150-298-424
Financing Cash Flow
Financing Cash FlowCr
-24010512-5-11438-136-692521
Net Cash Flow
Net Cash FlowCr
1-4053-93404244-56
Free Cash Flow
Free Cash FlowCr
26-2-1217984-37173119112-50
CFO To PAT
CFO To PAT%
165.582.593.4425.2353.7234.894.6145.187.0122.095.2
CFO To EBITDA
CFO To EBITDA%
55.736.422.3119.856.3129.042.387.356.598.260.3

Ratios

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
6221,3226288653642,6791,3172,3098,05915,49515,41226,483
Price To Earnings
Price To Earnings
23.328.452.552.922.633.420.814.227.059.942.658.5
Price To Sales
Price To Sales
1.22.31.21.30.52.91.41.95.210.57.611.5
Price To Book
Price To Book
3.42.51.11.30.53.41.62.36.310.28.313.1
EV To EBITDA
EV To EBITDA
9.714.018.117.85.619.410.88.817.447.626.737.4
Profitability Ratios
Profitability Ratios
GPM
GPM%
39.942.439.433.537.440.841.848.552.949.253.253.2
OPM
OPM%
15.818.49.68.813.415.715.022.829.721.928.430.6
NPM
NPM%
5.38.12.32.52.18.66.713.719.317.618.019.6
ROCE
ROCE%
18.712.23.84.07.812.78.820.430.121.123.628.1
ROE
ROE%
14.58.62.22.42.310.37.616.423.417.119.422.3
ROA
ROA%
5.25.31.11.41.36.14.610.316.411.912.414.9
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
6221,3226288653642,6791,3172,3098,05915,49515,41226,483
Price To Earnings
Price To Earnings
23.328.452.552.922.633.420.814.227.059.942.658.5
Price To Sales
Price To Sales
1.22.31.21.30.52.91.41.95.210.57.611.5
Price To Book
Price To Book
3.42.51.11.30.53.41.62.36.310.28.313.1
EV To EBITDA
EV To EBITDA
9.714.018.117.85.619.410.88.817.447.626.737.4
Profitability Ratios
Profitability Ratios
GPM
GPM%
39.942.439.433.537.440.841.848.552.949.253.253.2
OPM
OPM%
15.818.49.68.813.415.715.022.829.721.928.430.6
NPM
NPM%
5.38.12.32.52.18.66.713.719.317.618.019.6
ROCE
ROCE%
18.712.23.84.07.812.78.820.430.121.123.628.1
ROE
ROE%
14.58.62.22.42.310.37.616.423.417.119.422.3
ROA
ROA%
5.25.31.11.41.36.14.610.316.411.912.414.9
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Market CapitalizationMkt CapCr38,27931,85931,38526,48318,45518,2349,797
Close PriceClose₹1,800.70239.303,833.5020,642.001,609.30451.70517.60
IndustryIndustryPharma CRAMSPharma CRAMSPharma CRAMSPharma CRAMSPharma CRAMSPharma CRAMSPharma CRAMS
Price To EarningsPE101.2271.4758.5297.5632.35
Price To SalesPS16.143.2619.7111.4810.965.188.94
RevenueRevenueCr2,3719,7791,5932,3071,6843,5221,096
Revenue Growth TTMRev Gr TTM%15.5%9.4%45.2%50.5%10.7%-6.0%-7.0%
PAT Growth TTMPAT Gr TTM%31.4%-782.0%95.8%88.4%-104.1%-60.3%-19.0%
Market CapitalizationMkt CapCr38,27931,85931,38526,48318,45518,2349,797
Close PriceClose₹1,800.70239.303,833.5020,642.001,609.30451.70517.60
IndustryIndustryPharma CRAMSPharma CRAMSPharma CRAMSPharma CRAMSPharma CRAMSPharma CRAMSPharma CRAMS
Price To EarningsPE101.2271.4758.5297.5632.35
Price To SalesPS16.143.2619.7111.4810.965.188.94
RevenueRevenueCr2,3719,7791,5932,3071,6843,5221,096
Revenue Growth TTMRev Gr TTM%15.5%9.4%45.2%50.5%10.7%-6.0%-7.0%
PAT Growth TTMPAT Gr TTM%31.4%-782.0%95.8%88.4%-104.1%-60.3%-19.0%
Interviews